1360-1361 / 2437
Multicenter pilot study of radiochemotherapy as first-
line treatment for adults with medulloblastoma (NOA-
07)
Dagmar Beier
Results
N=30 pts ; 50% showed classic and desmoplastic/nodular
histology. 67% were classified into SHH subgroup without
TP53
alterations, 13% in WNT, 17% in non-WNT/non-SHH.
•
Four cycles of CT were feasible in the majority (
n =
21; 70.0%).
•
Hematological side effects and polyneuropathy were prevalent
toxicities.
•
The 3-year event-free survival rate was 66.6% at the time of
databank lock.
•
RT/CT did lead to considerable toxicity in adults, dose
reductions through out the first 4 CT cycles
•
Modifications on CT have to be performed